Previous 10 | Next 10 |
Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy PR Newswire Taldefgrobep alfa, in Phase 3 global clinical development for Spinal Muscular Atrophy, granted EU Orphan Drug Designation in addition to previously receiving Fast Track and...
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments PR Newswire Cash, cash equivalents, and marketable securities totaled $349.0 million as of June 30, 2023 Announced positive interim data from BHV-7000 EEG biomarker study d...
2023-07-27 12:50:02 ET Shares of Biohaven Ltd. (NYSE: BHVN) were crashing 27.5% lower at 11:50 a.m. ET on Thursday. This big sell-off came after the company provided updates on several programs. The most important news for investors is related to Biohaven's New Drug Application ...
2023-07-27 10:07:10 ET Gainers: Carmell Therapeutics ( CTCX ) +44% . Mallinckrodt ( MNK ) +35% . Evolus ( EOLS ) +28% . Lipocine ( LPCN ) +26% . Spok ( SPOK ) +23% . Losers: Mersana Therapeutics ( MRSN ) -77% . ...
2023-07-27 08:38:02 ET Mersana Therapeutics ( MRSN ) -74% announces topline data from UPLIFT clinical trial in patients with platinum-resistant Ovarian Cancer and strategic reprioritization. Biohaven ( BHVN ) -27% . Yellow Corporation ( YELL ) -26% . ...
Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates PR Newswire NEW HAVEN, Conn. , July 27, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a global clinical-s...
2023-06-14 13:09:06 ET Summary Biohaven offers a diverse portfolio of innovative drug development assets targeting various therapeutic areas, with a focus on neurodegenerative and neuroinflammatory conditions. The company's robust financials, diverse revenue streams, and recent pe...
2023-06-13 16:55:45 ET Summary Pfizer presents a buying opportunity as value has deepened following weak price action due to post-pandemic revenue concerns. Aggressive yet speculative acquisitions demonstrate a commitment to pipeline diversification in an effort to grow into ...
2023-06-06 14:44:35 ET Summary Biohaven Ltd is a spinout of assets from Biohaven Pharmaceutical - just before the parent company was acquired by Pfizer last year for >$11bn. Much of the management team that developed Biohaven Pharmaceuticals' Nurtec migraine therapy, plus six o...
2023-06-02 09:11:34 ET Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence . The big gain was sparked by the company's research and d...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-05-29 12:00:07 ET Brian Skorney from Robert W. Baird issued a price target of $58.00 for BHVN on 2024-05-29 09:57:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $30.31. The overall price target consensus is at $...
2024-05-29 11:00:21 ET Leonid Timashev from RBC Capital issued a price target of $59.00 for BHVN on 2024-05-29 09:14:00. The adjusted price target was set to $59.00. At the time of the announcement, BHVN was trading at $28.69. The overall price target consensus is at $23...